Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases
- 25 October 2022
- journal article
- research article
- Published by Taylor & Francis in Amyloid
- Vol. 30 (2) , 161-168
Abstract
This study characterised real-world treatment patterns, clinical outcomes, and cost-of-illness in patients with light-chain (AL) amyloidosis.Data were extracted from the US-based Optum® EHR and Cli...Keywords
This publication has 27 references indexed in Scilit:
- Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupInternal Medicine Journal, 2014
- Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Haematologica, 2014
- Economics of hematopoietic cell transplantationBlood, 2012
- Comparing VA and Private Sector Healthcare Costs for End-stage Renal DiseaseMedical Care, 2012
- Resource Use in the Last 6 Months of Life Among Medicare Beneficiaries With Heart Failure, 2000-2007Archives of internal medicine (1960), 2011
- Renal involvement in systemic amyloidosis: An Italian collaborative study on survival and renal outcomeNephrology Dialysis Transplantation, 2007
- Economic Burden of Haematological Adverse Effects in Cancer PatientsClinical Drug Investigation, 2007
- Light-Chain (AL) AmyloidosisClinical Journal of the American Society of Nephrology, 2006
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987